Latest News

Covagen enters into a strategic research collaboration and license agreement with Mitsubishi Tanabe for the development of bispecific FynomAbs.

ZURICH-SCHLIEREN, Switzerland, Oct. 17, 2012 - Covagen announced today that it has entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation (Osaka, Japan) and its fully owned subsidiary Tanabe Research Laboratories U.S.A., Inc. of San Diego Calif. (TRL). Under the agreement, Covagen will use its proprietary Fynomer...


Novel 3D Stent Demonstrates Safety and Efficacy in Treatment of PAD

Las Vegas, USA, 11 October 2012. – New data presented today at the annual VIVA (Vascular InterVentional Advances) conference has shown that a stent with unique three-dimensional geometry, BioMimics 3D™, demonstrated an excellent safety profile and promising clinical performance at both six and twelve months in the treatment of patients with peripheral arterial disease (PAD)...


Veryan Appoints Two Industry Veterans as Non-Executive Directors.

11 July 2012 – Vascular disease specialist Veryan has announced the appointments of Todd M. Pope and Jeffrey B. Jump as Non-Executive Directors. Both have many years’ experience of the medical device industry. “We are delighted to have acquired the expertise and guidance of two such veteran medical device specialists as Todd and Jeff”, commented Veryan Chief Executive...


< back to home page